Objective: HIV-infection and antiretroviral therapies are associated with energy dysfunction and lipid metabolism in adults. Our aim was to detect a possible carnitine deficiency in HIV-infected children on antiretroviral treatments. We analysed the relation among serum carnitine, its amino-acid precursors (methionine and lysine), clinical evaluation and antiretroviral therapy. Design and setting: Cross-sectional study performed in a tertiary care hospital. Subjects: A total of 79 HIV-infected children on antiretroviral therapy, monitored prospectively in our hospital. Interventions: Antiretroviral therapy included nucleoside analogues plus protease inhibitors and/or non-nucleoside analogues. Carnitine was analysed by an enzymatic-spectrometric procedure, and amino acids by ion exchange chromatography. Reference values of carnitine and amino acids were established in apparently healthy children who underwent presurgical analysis for minor surgery. Results: Serum free and total carnitine, acylcarnitines, methionine and lysine were significantly lower in HIV-infected children compared with our reference values for similar ages (Po0.0001; Student's t-test). Low carnitine values were observed in 37% of our HIV-infected children. A significantly positive correlation was observed between serum total carnitine and methionine or lysine (Po0.0001 and P ¼ 0.005, respectively; Pearson test). No relation was observed between serum carnitine and clinical stage of HIV infection, immunological or nutritional status or lipodystrophy. Free and total carnitine were significantly lower (P ¼ 0.002 and 0.033, respectively) in HIV-infected patients on protease inhibitors (N ¼ 56) compared with those on other treatments (N ¼ 23). Conclusions: Low serum carnitine concentration was observed in 37% of our HIV-infected children on antiretroviral therapy. Malabsorption or defective synthesis may also account for the low serum carnitine values detected in these patients. Sponsorship: Grant FIS 99/1270.
Introduction
HIV infection can lead to severe and multisystem abnormalities. The pathogenic mechanisms combine the primary effect of the HIV virulence with the secondary metabolic disturbances triggered by opportunistic infections, nutritional deficiencies, malabsorption and drug toxicity (Mintz, 1995) . The identification of some environmental pathogenetic factors, such as nutritional deficiencies, may lead to their correction, with the subsequent improvement of the prognosis and quality of life in these patients. Micronutrient deficiency is frequent in HIV-infected adults (Bogden et al, 1990) , but there are few data in the literature about possible deficiencies in paediatric patients (Periquet et al, 1995) .
There is a growing body of evidence of HIV-associated or drug-induced myopathies in adult patients with AIDS. Mitochondrial dysfunction and carnitine deficiency seem to be involved in these neurological complications .
Carnitine (b-hydroxy-g-trimethylamonium butyrate) is derived from dietary sources (red meat, poultry, fish and dairy products) and endogenous synthesis. In humans, carnitine is synthesized in liver and kidney from proteinbound lysine and methionine (Carter et al, 1995) . Carnitine serves two major functions: the transport of fatty acylcoenzyme A across the inner mitochondrial membrane for boxidation and the modulation of intracellular CoA homeostasis. Recently, a role in the regulation of caspase activities for L-carnitine has been reported (Mutomba et al, 2000) . Carnitine deficiency may be primary or secondary. The former is defined as a decrease of intracellular carnitine content that impairs fatty acid oxidation and is not associated with other primary defects that might deplete tissue carnitine stores. Secondary carnitine deficiencies are associated with inborn metabolic errors, acquired medical conditions, nutritional deficiencies or iatrogenic states (Pons & DeVivo, 1995) .
Serum carnitine deficiency as well as carnitine depletion in peripheral blood mononuclear cells and in muscle has been described in HIV-infected adults (De Simone et al, 1992 Dalakas et al, 1994) , but very little data on carnitine status have been reported in children (Mintz, 1995) . Carnitine depletion seems to be associated with the use of antiretroviral therapies, especially zidovudine (AZT) . Related to this, L-carnitine supplementation seems to improve AZT-induced myopathies and prevent further myotube destruction (Semino-Mora et al, 1994) .
As a part of the nutritional evaluation of a group of HIVinfected children periodically monitored at our hospital, our aim was to detect a possible carnitine deficiency in HIVinfected children on antiretroviral therapy. We tried to find a relation between serum carnitine, its amino-acid precursors (methionine and lysine), nutritional status and antiretroviral therapy.
Materials and methods

Patients
We included 79 HIV-infected children (age range: 1-15 y; mean: 8.7 y) periodically monitored in the paediatrics department of our hospital. Blood samples for this study were collected during routine clinical control and analytical monitoring, which included haematological, immunological, virological and nutritional evaluation, and liver function test. Clinical stages of the disease were based on the 1994 revised guidelines for HIV-1 infection in children (Centers for Disease Control and Prevention). Seven patients were severely symptomatic and immunodepressed (C3, B3), 31 children were moderately symptomatic and immunodepressed (B1, B2, A2), 15 patients were severely symptomatic and moderately immunodepressed (C1, C2) and 26 children were asymptomatic or with slight symptoms and nonimmunodepressed (N1, A1). Nutritional status of these patients according to the McLaren Index (McLI; Weight (kg)/Size (cm) Â Size (P50 for age)/Weight (P50 for age)) was the following: 17 patients were undernourished (McLIo90), 46 patients were normal (McLI: 90-110), eight patients showed excessive weight (McLI: 111-120), and eight patients were obese (McLI4 120). Lipodystrophy was defined as a collection of morphological (abnormal fat redistribution, accumulation or wasting) and metabolic (increased triglycerides and/or cholesterol and insulin resistance) abnormalities linked with the use of antiretroviral therapy. Lipodystrophy was observed in 10 patients by anthropometry and questionnaires of morphological changes directed to the patients and/or parents. Treatment consisted of nucleoside analogues (zidovudine, didanosine, stavudine, lamivudine and abacavir), protease inhibitors (saquinavir, ritonavir, indinavir and nelfinavir) and non-nucleoside analogues (nevirapine and efavirenz), as well as a combination of all these drugs (Table 1) .
Reference values were established in our paediatric population (age range: 1-16 y, mean: 9.1 y) by measurement of plasma carnitine (N ¼ 31) and amino acids (N ¼ 88) in apparently healthy children (based on history and analytical data) who underwent presurgical analysis for minor surgery.
The Hospital Ethics Committee approved the study. Blood samples were obtained after informed consent from the Table 1 Treatment characteristics of the HIV-infected children 
Laboratory studies
Fasting venous blood samples for measurement of carnitine and amino-acid profile were collected. Aliquots were prepared, frozen at -401C and analysed within the following fortnight at the same hospital laboratory. Carnitine was analysed by a spectrometric procedure adapted to the Cobas Fara II analyser (Artuch et al, 1997) , and amino acids by ion exchange chromatography with a Biochrom 20, LKB Pharmacia Biotech autoanalyser (Moyano et al, 1998) .
Patients' serum carnitine and amino-acid concentrations were compared with our reference values, which are independent of age and sex for the paediatric population. Low serum carnitine concentration was considered to be present when total or free carnitine values were below two standard deviations of our mean reference values (total carnitineo33 mmol/l and free carnitine o20 mmol/l).
Quantitative HIV-1 RNA assay was performed using a quantitative reverse transcriptase (RT) PCR assay (Amplicor monitor, Roche Diagnostic system).
Statistical analysis
Serum carnitine and amino-acid values follow a Gaussian distribution (Kolmogorov-Smirnov), so the Student's t-test was applied to compare patients' concentrations to reference values, as well as those found in patients treated with different antiretroviral drugs, with a 95% confidence interval. The correlation between carnitine and amino-acid concentrations was analysed using the Pearson test. P values below 0.05 were considered to indicate statistical significance. Statistical analyses were performed using the statistical package SPSS (version 10.0).
Results
Clinical data, stages, immunological and virological status, liver function and nutritional status of the HIV-infected children are summarized in Table 2 . Serum free and total carnitine, acylcarnitines, methionine and lysine were significantly lower in HIV-infected children compared with our reference values for similar ages (Po0.0001; Student's t-test) (Table 3, Figure 1 ). Low total carnitine values were observed in 29/79 (37%) and low free carnitine in 22/79 (28%) of our HIV-infected children.
A significantly positive correlation was observed between serum total carnitine and methionine or lysine (Po0.0001 and P ¼ 0.005, respectively; Pearson test). No relation was observed between serum carnitine and clinical stage of HIV infection (CDC, 1994) , immunological or nutritional status or lipodystrophy.
As regards antiretroviral therapy, free and total carnitine were significantly lower (P ¼ 0.002 and 0.033, respectively; Student's t-test) in HIV-infected patients on protease inhibitors (N ¼ 56) compared with those on other treatments (N ¼ 23) (Table 4) .
Discussion
Carnitine deficiency may occur in adult HIV-infected patients (De Simone et al, 1992 , but also in children, according to our results. We found low free carnitine levels in 28% of our HIV-infected children and low total carnitine in 37% of them, with most of these patients (24%) showing free and total carnitine deficient values. These results are similar to those reported by other authors (Mintz, 1995) . Decreased serum carnitine concentrations in many cases reached extremely low values, since 15% of our HIV-infected children showed free carnitine concentrations 15 mmol/l while total carnitine values were 25 mmol/l.
The identification of the causes of these carnitine deficiencies is a complex matter, and most probably a combination of multiple factors is involved in these decreased levels. In general, secondary carnitine deficiency may result from dietary restriction derived from special diets, such as occurs in some inborn errors of metabolism treated with natural protein-restricted diets (phenylketonuria, urea cycle defects and organic acidurias) (Vilaseca et al, 1993; Pons & DeVivo, 1995) , which are the major source of exogenous carnitine. Low concentrations of precursor amino acids (Melegh et al, 1993) , owing to malnutrition or malabsorption, is another possible cause, since malabsorption and 'wasting' syndrome is a common condition in HIV-infected adults and children (Mintz, 1995; Kotler, 1998) . Low levels of precursors, such as amino acids (methionine and lysine), vitamins (ascorbic acid, niacin and vitamin B6) or other micronutrients (iron), may also impair carnitine biosynthesis (Carter et al, 1995) . However, malabsorption, rather than malnutrition, may account for the selective micronutrient deficiency found in our patients, since plasma methionine, lysine and folate were significantly low while serum cobalamin was normal in a previous study (Vilaseca et al, 2001) . Cobalamin, methionine and lysine derive from similar animal protein sources, which suggested that animal protein malnutrition was uncommon in our patients, as indicated by their parents. Low carnitine concentrations were also found in 29 adult patients with adequate nutrition (De Simone et al, 1992) . The significant correlation found in our patients between methionine or lysine and free or total carnitine levels may also suggest a selective malabsorption of these compounds, as already described for other micronutrients (Revell et al, 1991) . A further possible factor involved in carnitine deficiency is increased excretion derived from the wasting syndrome, together with the described disturbance in energy metabolism, which may affect renal function and carnitine reabsorption. Carnitine depletion through increased renal excretion was reported in six adult patients on nucleoside analogue therapy (Davis et al, 1998) .
Finally, drug toxicity, either from antiretroviral therapies or from drugs applied for opportunistic infections, may cause secondary metabolic changes leading to serum or tissue carnitine deficiency (Mintz, 1995) . Numerous studies have concluded that mitochondrial dysfunction and carnitine depletion are involved in the myopathic processes associated with HIV infection and its drug therapies, especially zidovudine treatment (Dalakas et al, 1990 Arnaudo et al, 1991; Walter et al, 1991; Simpson, 1992; Campos & Arenas, 1994) . Muscle carnitine deficiency and lipid storage as well as mitochondrial DNA depletion were described in well-nourished adult HIV-infected patients treated with zidovudine, many of whom complained of myopathic signs and symptoms (fatigue, myalgia, weakness and increased serum creatine phosphokinase) (Dalakas et al, 1990, 1994) . Ragged-red fibres as well as hepatic steatosis, lactic acidosis and cytochrome c deficiency have also been described in nucleoside analogue-treated patients Lenzo et al, 1997; Sundar, 1997; Megarbane et al, 1999; Brinkman et al, 1999; Carr et al, 2000) . The suggested causes of these induced myopathies may be related to the reduction of muscle carnitine, probably because of decreased carnitine uptake. Although the cause of muscle carnitine deficiency remains unclear, some authors have hypothesized that the reduced energy within the muscle cells causes a shift toward the glycolytic pathway resulting in excess lactate and acetyl-coenzyme A production. This may esterify free carnitine which is exported by the muscle mitochondria and excreted by the kidney . Another hypothesis is that the muscle mitochondrial dysfunction (hepatic steatosis, lactic acidosis and myopathy) caused especially by nucleoside analogue reverse transcriptase inhibitor therapy (mitochondrial DNA polymerase gamma inhibition resulting in impaired synthesis of the mitochondrial enzyme that generates ATP) (Brinkman et al, 1998) may impair the energy-dependent carnitine uptake from the blood, resulting in carnitine deficiency . However, this hypothesis does not explain serum carnitine deficiency, which is supposed to be determined by nutritional factors or kidney dysfunction. The utilization of carnitine to remove drug-induced toxic metabolites seems improbable owing to the low acyl-carnitine levels and normal acyl-carnitine/free-carnitine ratio found in our patients (Table 3) . On the other hand, a syndrome of peripheral lipodystrophy, central adiposity, dyslipidaemia and insulin resistance has been observed in patients treated on protease inhibitors (Carr et al, 1998a) . Carr hypothesized that protease inhibitor treatment may lead to unspecific interactions with two proteins (cytoplasmatic-acid binding protein type-1 and lowdensity lipoprotein-related protein) that regulate lipid metabolism (Carr et al, 1998b) . Under this hypothesis, the resulting inhibition causes hyperlipidaemia and contributes to central fat deposition and insulin resistance. The significantly lower carnitine values found in our HIV-infected children on PI treatment compared with other therapies may be related with the altered lipid metabolism reported in these patients, although further investigation should be performed to confirm these findings.
As already noted by other authors, a secondary carnitine deficiency may further exacerbate impaired immune and neurological function of HIV-infected patients, contributing to lipid metabolism disturbances (Mintz, 1995) . Carnitine supplementation to normalize deficient values seems to have no adverse consequences (De Simone et al, 1993; Semino-Mora et al, 1994; Pons & DeVivo, 1995; Cifone et al, 1997; Famularo et al, 1997; Moretti et al, 1998) , but rather provides an antiapoptotic action (Famularo et al, 1999; Mutomba et al, 2000) and an improvement in energy metabolism (Semino-Mora et al, 1994; Dalakas et al, 1994; Claessens et al, 2000) , apparently independent of previous defective carnitine values (Famularo et al, 1999) . Therefore, carnitine measurement seems advisable in HIV-infected children so as to be able to normalize decreased serum and, probably, tissue levels.
In conclusion, low serum carnitine was observed in 37% of our HIV-infected children. Malabsorption or defective synthesis may also account for the low carnitine values detected in these patients.
